96 related articles for article (PubMed ID: 28129617)
21. Is testicular dysgenesis syndrome a genetic, endocrine, or environmental disease, or an unexplained reproductive disorder?
Xing JS; Bai ZM
Life Sci; 2018 Feb; 194():120-129. PubMed ID: 29183799
[TBL] [Abstract][Full Text] [Related]
22. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
23. Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters.
Kharlyngdoh JB; Pradhan A; Asnake S; Walstad A; Ivarsson P; Olsson PE
Environ Int; 2015 Jan; 74():60-70. PubMed ID: 25454221
[TBL] [Abstract][Full Text] [Related]
24. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
25. Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists.
Ng HW; Zhang W; Shu M; Luo H; Ge W; Perkins R; Tong W; Hong H
BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S4. PubMed ID: 25349983
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
27. Androgen and Progesterone Receptors Are Targets for Bisphenol A (BPA), 4-Methyl-2,4-bis-(P-Hydroxyphenyl)Pent-1-Ene--A Potent Metabolite of BPA, and 4-Tert-Octylphenol: A Computational Insight.
Rehan M; Ahmad E; Sheikh IA; Abuzenadah AM; Damanhouri GA; Bajouh OS; AlBasri SF; Assiri MM; Beg MA
PLoS One; 2015; 10(9):e0138438. PubMed ID: 26379041
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic insight into human androgen receptor-mediated endocrine-disrupting potentials by a stable bioluminescence resonance energy transfer-based dimerization assay.
Lee SH; Hong KY; Seo H; Lee HS; Park Y
Chem Biol Interact; 2021 Nov; 349():109655. PubMed ID: 34520754
[TBL] [Abstract][Full Text] [Related]
29. [Testicular dysgenesis syndrome: an update].
Xu ZM; Tang DX
Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1113-6. PubMed ID: 21348205
[TBL] [Abstract][Full Text] [Related]
30. Reprint of "In silico methods in the discovery of endocrine disrupting chemicals".
Vuorinen A; Odermatt A; Schuster D
J Steroid Biochem Mol Biol; 2015 Sep; 153():93-101. PubMed ID: 26291836
[TBL] [Abstract][Full Text] [Related]
31. Computational insights into the molecular interactions of environmental xenoestrogens 4-tert-octylphenol, 4-nonylphenol, bisphenol A (BPA), and BPA metabolite, 4-methyl-2, 4-bis (4-hydroxyphenyl) pent-1-ene (MBP) with human sex hormone-binding globulin.
Sheikh IA; Tayubi IA; Ahmad E; Ganaie MA; Bajouh OS; AlBasri SF; Abdulkarim IMJ; Beg MA
Ecotoxicol Environ Saf; 2017 Jan; 135():284-291. PubMed ID: 27750096
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
33. Computer-aided identification of novel protein targets of bisphenol A.
Montes-Grajales D; Olivero-Verbel J
Toxicol Lett; 2013 Oct; 222(3):312-20. PubMed ID: 23973438
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential endocrine disrupting chemicals using gene expression biomarkers.
Corton JC; Kleinstreuer NC; Judson RS
Toxicol Appl Pharmacol; 2019 Oct; 380():114683. PubMed ID: 31325560
[TBL] [Abstract][Full Text] [Related]
35. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
[TBL] [Abstract][Full Text] [Related]
36. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
37. Natural extranuclear androgen receptor ligands as endocrine disruptors of cancer cell growth.
Kampa M; Notas G; Castanas E
Mol Cell Endocrinol; 2017 Dec; 457():43-48. PubMed ID: 28212843
[TBL] [Abstract][Full Text] [Related]
38. Classifying chemical mode of action using gene networks and machine learning: a case study with the herbicide linuron.
Ornostay A; Cowie AM; Hindle M; Baker CJ; Martyniuk CJ
Comp Biochem Physiol Part D Genomics Proteomics; 2013 Dec; 8(4):263-74. PubMed ID: 24013142
[TBL] [Abstract][Full Text] [Related]
39. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
40. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
